Can removing the main tumor boost targeted therapy in advanced lung cancer?

NCT ID NCT07177092

Not yet recruiting Disease control Sponsor: Jianxing He Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks at whether surgically removing the primary lung tumor before starting the targeted drug osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer. About 118 patients with stage III-IV cancer will be randomly assigned to get surgery plus osimertinib or osimertinib alone. The goal is to see if the combination delays cancer progression and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (a targeted therapy pill) and surgery to remove the main lung tumor
What this could lead to: If successful, this could show that combining surgery with targeted therapy helps people with advanced EGFR-mutant lung cancer live longer without their disease getting worse.
What could go wrong: This is a small, early-phase (phase 2) study with only 118 people. Surgery in advanced cancer carries risks like infection or complications, and the added benefit over osimertinib alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR NON-SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.